Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VEN+AZA-5 · 1 trial · 1 indication
Bone marrow assessments will be performed at least at screening, at the end of cycle 1, after cycle 4 and after cycle 6 resp. end of treatment (EOT). Criteria for disease status / response assessment follow the ELN-2022 recommendations .
| Arm | Type | Description |
|---|---|---|
| VEN+AZA-5 | EXPERIMENTAL | Azacitidine (AZA) 75 mg/m2, d1-5 of each 28 day cycle (SC) in combination with Venetoclax (VEN): 400 mg daily (orally) |
| Name | Type | Description |
|---|---|---|
| VEN+AZA-5 | DRUG | Up to 6 cycles: Azacitidine (AZA) 75 mg/m2, d1-5 of each 28 day cycle (SC) in combination with Venetoclax (VEN): 400 mg daily (orally) |
Key Inclusion Criteria: * Confirmed diagnosis of AML by World Health Organization (WHO) criteria 2016 * Ineligible for treatment with a standard cytarabine and anthracycline induction regimen due to age or comorbidities * Age ≥ 18 years * Life expectancy of at least 12 weeks Key Exclusion Criteria...
VEN+AZA-5 is an investigational combination therapy being studied for the treatment of Acute Myeloid Leukemia (AML). It is specifically being evaluated in untreated AML patients who are not eligible for standard induction therapy. The drug is currently in Phase 2 clinical development.
VEN+AZA-5 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The company is conducting a Phase 2 clinical trial to evaluate this combination therapy in patients with Acute Myeloid Leukemia.
VEN+AZA-5 is currently in Phase 2 clinical development. It is an investigational therapy and has not been approved by regulatory authorities. The ongoing Phase 2 trial is actively recruiting participants, though enrollment is not yet complete.
VEN+AZA-5 is being evaluated in a single Phase 2 clinical trial with the identifier NCT05833438. This trial is titled 'Venetoclax in Combination With 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy' and is being conducted in Germany.
VEN+AZA-5 combines venetoclax, a BCL-2 inhibitor, with azacitidine, a hypomethylating agent. This combination is designed to target the mechanisms that allow AML cells to survive and proliferate. The therapy is being studied in patients with Acute Myeloid Leukemia who are not candidates for standard induction therapy.